Phaseline

Targets › THBD

THBD (Thrombomodulin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Aug 2028.

Endothelial cell receptor that plays a critical role in regulating several physiological processes including hemostasis, coagulation, fibrinolysis, inflammation, and angiogenesis. Acts as a cofactor for thrombin activation of protein C/PROC on the surface of vascular endothelial cells leading to initiation of the activated protein C anticoagulant pathway. (UniProt, P07204)

Open in Phaseline: the race on THBD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisRecombinant human Thrombomodulin (rhTM)
Thrombomodulin mimetic with anticoagulant and anti-inflammatory properties
THBDPhase 2SepsisAug 2028

Conditions

Sepsis (1)

Modalities

mixed (1)

Companies

Assistance Publique - Hôpitaux de Paris (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.